News|Articles|September 1, 2006

Easy Freezing of Recalcitrant Keratoses

Application of liquid nitrogen often must be repeated several times when used to treat thick seborrheic keratoses--and still may be ineffective. For an immediate and excellent cosmetic result, try liquid nitrogen for 5 seconds, followed by gentle curettage. Any pinpoint bleeding can be stopped with aluminum chloride.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Easy Freezing of Recalcitrant Keratoses

Related Content

Tirzepatide Plus Ixekizumab Improves Outcomes in Psoriatic Arthritis With Obesity: AAD 2026

Lebrikizumab Maintains Efficacy Through 4 Years in Moderate-to-Severe Atopic Dermatitis: AAD 2026

Icotrokinra for Moderate-to-Severe Plaque Psoriasis: A Dermatologist's Guide for Primary Care

FDA Approves Icotrokinra (Icotyde): First Oral IL-23 Receptor Antagonist for Moderate-to-Severe Plaque Psoriasis

Weight Loss Interventions Linked to Clinically Meaningful Psoriasis Improvement

Latest CME

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Uniting Heart and Kidney Care: Optimizing Outcomes in Cardio-Kidney-Metabolic Disorders

Tennessee Oncology Practice Society

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Breaking the Demodex Blepharitis Cycle: The Importance of Early Intervention

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Southern California Psychiatry Conference

Show Me the Data™ New Frontiers in the Treatment of Ovarian Cancer

25th Annual International Congress on the Future of Breast Cancer® East

Retina Updates in Montréal

25th Annual International Congress on the Future of Breast Cancer® West

Indiana Oncology Society

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Community Practice Connections™: 16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Looking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 2)

Optimizing Treatment for Biliary Tract Cancers

24th Annual International Congress on the Future of Breast Cancer® East

Cross-Disease Integration of Immunotherapy Innovations

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Radioligand Therapy 101: The Science Behind the Strategy

Imaging Matters: Decoding PSMA PET for Better Decision-Making

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Pathways to Progress: RAS in GI Cancers (Spotlight CE Session)

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, Maintenance, and Beyond! – Arizona

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Obesity: New and Emerging Strategies to Optimally Manage a Chronic Disease

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Iowa Oncology Society

Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation